SCHEDULE: State Street Discloses Stake in BioCryst Pharmaceuticals

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 4.9% of BioCryst Pharmaceuticals Inc. common stock as of March 31, 2026.

Summary

• State Street Corporation has reported beneficial ownership of 12,208,360 shares of BioCryst Pharmaceuticals Inc. common stock.
• This holding represents 4.9% of the total class of securities.
• The filing date for this report is March 31, 2026.
• State Street Corporation is classified as a holding company (HC) for reporting purposes.
• The filing indicates shared power to vote (11,618,245 shares) and shared power to dispose (12,208,360 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance information about the company itself.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from BioCryst Pharmaceuticals Inc.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by State Street Corporation indicates a significant institutional holding in BioCryst Pharmaceuticals Inc., a biotechnology company. Such filings are common for large asset managers and signal their investment positions in publicly traded entities.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding institutional ownership, which can be a factor in market perception and stock liquidity.
• Management: Awareness of significant institutional holdings can influence strategic decisions and investor relations efforts.

Key Dates

Keywords

Schedule 13G, State Street Corporation, BioCryst Pharmaceuticals Inc., Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor